세계의 젬시타빈 염산염 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Gemcitabine Hydrochloride Market was valued at USD 788.6 million in 2024 and is projected to expand at a CAGR of 6.7% from 2025 to 2034. The increasing prevalence of cancer worldwide, coupled with a growing reliance on chemotherapy drugs, is driving market growth. As cases of pancreatic, lung, and bladder cancer continue to rise, demand for effective chemotherapy treatments like gemcitabine hydrochloride is expected to surge. This widely used chemotherapy drug plays a crucial role in cancer treatment protocols, making it an essential component of oncological care. The increasing availability of gemcitabine, driven by pharmaceutical advancements and rising healthcare investments, is further boosting its market potential.

Ongoing research and development efforts are focused on enhancing the efficacy and delivery of gemcitabine hydrochloride, leading to new formulations and improved administration methods. Pharmaceutical companies are investing heavily in innovation, creating novel drug delivery systems that increase bioavailability and reduce side effects. These advancements are making gemcitabine hydrochloride more adaptable across different treatment plans, improving patient outcomes and survival rates. The rising awareness of early cancer diagnosis, coupled with technological progress in precision medicine, is also influencing market dynamics. As more healthcare providers prioritize effective chemotherapy regimens, the adoption of gemcitabine hydrochloride is set to rise.

The market is segmented into branded and generic drugs, with the generic segment maintaining a dominant position. Generic gemcitabine held a market value of USD 516.6 million in 2024, reflecting steady growth in recent years. The affordability of generic chemotherapy drugs has made them widely accessible, particularly in lower-income regions where healthcare costs remain a concern. The proven effectiveness of generic gemcitabine, combined with its lower price point, continues to drive its popularity in cancer treatment. As healthcare systems strive to offer cost-effective cancer therapies, the demand for generic gemcitabine is expected to remain strong.

Market segmentation also extends to the type of cancer treated, with pancreatic cancer accounting for 32.6% of the market share in 2024. The rising incidence of pancreatic cancer, along with gemcitabine's established role as a first-line treatment, has made this segment a key revenue driver. As one of the most aggressive and challenging cancers to treat, pancreatic cancer requires effective chemotherapy options, and gemcitabine has demonstrated significant efficacy in improving survival rates for patients in advanced stages. The drug's continued use in this segment underscores its critical role in modern oncology treatment strategies.

North America dominated the global market, holding 45.6% of the total market share in 2024. The U.S. market alone was valued at USD 324 million, driven by a high incidence of pancreatic cancer and strong healthcare infrastructure. Government initiatives such as Medicare and Medicaid have played a vital role in making cancer treatments more accessible. Financial assistance programs and favorable reimbursement policies have enabled a larger patient base to access gemcitabine hydrochloride, contributing to the region's market leadership. With ongoing healthcare reforms and increased investment in oncology research, North America is expected to maintain its strong position in the global gemcitabine hydrochloride market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cancer
    • 3.2.1.2 Advancement in drug delivery system
    • 3.2.1.3 Increasing adoption of generic drugs
    • 3.2.1.4 Expanding application in combination therapies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Availability of alternative therapies
    • 3.2.2.2 Stringent regulatory approvals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Cancer statistics landscape
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Branded drugs
• 5.3 Generic drugs

Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Lung cancer
• 6.3 Breast cancer
• 6.4 Pancreatic cancer
• 6.5 Ovarian cancer
• 6.6 Bladder cancer
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty cancer clinics
• 7.4 Ambulatory surgical centers (ASCs)
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Accord Healthcare
• 9.2 Apotex
• 9.3 Aurobindo Pharma
• 9.4 CHEPLAPHARM Group
• 9.5 Dr. Reddy’s Laboratories
• 9.6 Fresenius Kabi
• 9.7 Mylan
• 9.8 NorthStar Rx
• 9.9 Pfizer (Hospira Australia)
• 9.10 Sun Pharmaceutical
• 9.11 Teva Pharmaceuticals
• 9.12 Zydus